Andere Sprachen Hansae Yes24 Holdings Co., Ltd

Aktien

A016450

KR7016450009

A016450

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 26.04.2024			% 5 Tage	% 1. Jan.
4’720 ^KRW	-0.21%		+1.72%	-3.67%

20.03.	Hansae Yes24 Holdings Co., Ltd meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
2023	Hansae Yes24 Holdings Co., Ltd meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Hansa Biopharma interim report January-March 2024	18.04.
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	12.04.
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	02.04.
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	21.03.
Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	20.03.
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	22.02.
Hansa Biopharma Year-end report January-December 2023	02.02.
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	06.01.
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	15.12.
Hansa Biopharma Nomination Committee formed	13.12.
Hansa Biopharma - Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 Trial in Guillain-Barre Syndrome	08.12.
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables	05.12.
Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota	27.11.
Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Hansa Biopharma Interim Report January-September 2023	26.10.23
Hansa Biopharma - Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study	18.10.23
Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study	17.10.23
Hansa Biopharma - Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients	12.10.23
Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients	11.10.23
Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487	09.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hansae Yes24 Holdings Co., Ltd

Aktien

A016450

KR7016450009

A016450

Andere Sprachen

Filter